Kura/Kyowa Kirin’s Komzifti Comes With QTc Safety Advantage

 
• By Alaric DeArment
  
The FDA approved Kura and Kyowa Kirin's Komzifti for relapsed/refractory NPM1-mutant AML. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip